Mitsuo Terada

673 total citations
36 papers, 402 citations indexed

About

Mitsuo Terada is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Mitsuo Terada has authored 36 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Molecular Biology and 10 papers in Cancer Research. Recurrent topics in Mitsuo Terada's work include Breast Cancer Treatment Studies (7 papers), Breast Lesions and Carcinomas (5 papers) and HER2/EGFR in Cancer Research (5 papers). Mitsuo Terada is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), Breast Lesions and Carcinomas (5 papers) and HER2/EGFR in Cancer Research (5 papers). Mitsuo Terada collaborates with scholars based in Japan, United States and Switzerland. Mitsuo Terada's co-authors include Yukío Shimosato, Shaw Watanabe, T Hirota, Hitoshi Tsuda, Hiroshi Yamamoto, Shoichiro Tsugane, S Hirohashi, Takamasa Yoshida, Jun Yokota and T Sugimura and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Mitsuo Terada

32 papers receiving 390 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mitsuo Terada Japan 11 239 140 112 81 70 36 402
Samuel G.W. Ow Singapore 12 255 1.1× 128 0.9× 99 0.9× 66 0.8× 54 0.8× 50 426
Julie K. Jang United States 11 220 0.9× 87 0.6× 100 0.9× 93 1.1× 70 1.0× 32 503
Cosmin Moldovan Romania 9 173 0.7× 198 1.4× 44 0.4× 63 0.8× 91 1.3× 38 377
Afef Khanfir Tunisia 11 186 0.8× 82 0.6× 70 0.6× 116 1.4× 52 0.7× 80 400
Shawn Steen United States 11 148 0.6× 99 0.7× 80 0.7× 45 0.6× 60 0.9× 22 334
Raquel Andrés Spain 13 161 0.7× 148 1.1× 166 1.5× 156 1.9× 36 0.5× 32 499
Chizuko Kanbayashi Japan 12 355 1.5× 179 1.3× 114 1.0× 275 3.4× 76 1.1× 36 593
Gian Paolo Spinelli Italy 15 190 0.8× 131 0.9× 132 1.2× 158 2.0× 91 1.3× 50 514
I Zbieranowski Canada 9 243 1.0× 78 0.6× 168 1.5× 126 1.6× 62 0.9× 16 503
Su-Mi Chung South Korea 11 124 0.5× 56 0.4× 54 0.5× 85 1.0× 42 0.6× 15 399

Countries citing papers authored by Mitsuo Terada

Since Specialization
Citations

This map shows the geographic impact of Mitsuo Terada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitsuo Terada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitsuo Terada more than expected).

Fields of papers citing papers by Mitsuo Terada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitsuo Terada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitsuo Terada. The network helps show where Mitsuo Terada may publish in the future.

Co-authorship network of co-authors of Mitsuo Terada

This figure shows the co-authorship network connecting the top 25 collaborators of Mitsuo Terada. A scholar is included among the top collaborators of Mitsuo Terada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitsuo Terada. Mitsuo Terada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Terada, Mitsuo, et al.. (2026). Predictive factors and prognostic significance of HER2-low early breast cancer with long-term follow-up. Surgical Oncology. 64. 102360–102360.
2.
Matsumoto, Naoya, Yumi Wanifuchi‐Endo, Takashi Fujita, et al.. (2025). Prognosis, clinicopathological characteristics, and treatment patterns of patients with ER-intermediate-positive breast cancer undergoing long-term follow-up. ESMO Open. 10(4). 104508–104508.
3.
Sasaki, Keita, Ryunosuke Machida, Tadahiko Shien, et al.. (2024). Status of incremental costs of first-line treatment recommended in Japanese clinical guidelines for metastatic breast cancer patients. Japanese Journal of Clinical Oncology. 54(10). 1093–1099. 1 indexed citations
4.
Terada, Mitsuo, Kazuki Nozawa, Yumi Wanifuchi‐Endo, et al.. (2023). Fact-Checking Cancer Information on Social Media in Japan: Retrospective Study Using Twitter. JMIR Formative Research. 7. e49452–e49452. 10 indexed citations
5.
Nozawa, Kazuki, Mitsuo Terada, Yukinori Ozaki, et al.. (2023). Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan. Breast Cancer. 30(4). 657–665. 7 indexed citations
6.
7.
8.
Katsuta, Eriko, Naoto Kondo, Yumi Wanifuchi‐Endo, et al.. (2022). Low HECTD1 mRNA expression is associated with poor prognosis and may be correlated with increased mitochondrial respiratory function in breast cancer. PubMed Central. 2 indexed citations
9.
Kato, Akiko, Naoto Kondo, Yumi Wanifuchi‐Endo, et al.. (2022). Low TINAGL1 expression is a marker for poor prognosis in breast cancer. Journal of Cancer Research and Clinical Oncology. 149(8). 4771–4782. 5 indexed citations
10.
Uchida, Megumi, Naoto Kondo, Yumi Wanifuchi‐Endo, et al.. (2021). Predictive factors for patients who need treatment for chronic post-surgical pain (CPSP) after breast cancer surgery. Breast Cancer. 28(6). 1346–1357. 7 indexed citations
11.
Kotani, Haruru, Mitsuo Terada, Makiko Mori, et al.. (2021). Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial. BMC Cancer. 21(1). 548–548. 13 indexed citations
12.
Nishikawa, Sayaka, Tae‐Sun Kim, Naoto Kondo, et al.. (2021). Low RAI2 expression is a marker of poor prognosis in breast cancer. Breast Cancer Research and Treatment. 187(1). 81–93. 11 indexed citations
13.
Iwase, Madoka, Masaya Hattori, Masataka Sawaki, et al.. (2019). Presence of small residual malignant lesions in pathologic complete response after neo‐adjuvant chemotherapy in patients with breast cancer. The Breast Journal. 25(6). 1303–1305.
14.
Terada, Mitsuo, Akiyo Yoshimura, Masataka Sawaki, et al.. (2019). Patient-reported outcomes and objective assessments with arm measurement and bioimpedance analysis for lymphedema among breast cancer survivors. Breast Cancer Research and Treatment. 179(1). 91–100. 19 indexed citations
15.
Terada, Mitsuo, Masataka Sawaki, Masaya Hattori, et al.. (2019). A case of giant cell tumor of the breast, clinically suspected as malignant breast tumor. SHILAP Revista de lepidopterología. 5(1). 77–77. 8 indexed citations
16.
Mori, Makiko, Haruru Kotani, Masataka Sawaki, et al.. (2019). Amyloid tumor of the breast. SHILAP Revista de lepidopterología. 5(1). 31–31. 11 indexed citations
17.
Terada, Mitsuo, Yayoi Adachi, Masataka Sawaki, et al.. (2018). Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes. Breast Cancer Research and Treatment. 172(1). 1–7. 20 indexed citations
18.
Adachi, Yayoi, Masataka Sawaki, Masaya Hattori, et al.. (2018). Comparison of sentinel lymph node biopsy between invasive lobular carcinoma and invasive ductal carcinoma. Breast Cancer. 25(5). 560–565. 15 indexed citations
19.
Tsuda, Hitoshi, S Hirohashi, Yukío Shimosato, et al.. (1990). correlation between histologic grade of malignancy and copy number of c-erbb-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer. 65(8). 1794–1800. 137 indexed citations
20.
Yokota, Jun, Takamasa Yoshida, M. Noguchi, et al.. (1989). Heterogeneity of lung cancer cells with respect to the amplification and rearrangement of myc family oncogenes. Lung Cancer. 5(6). 13–13. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samuel G.W. Ow Breakdown of academic impact, for papers by Julie K. Jang Breakdown of academic impact, for papers by Cosmin Moldovan Breakdown of academic impact, for papers by Afef Khanfir Breakdown of academic impact, for papers by Shawn Steen Breakdown of academic impact, for papers by Raquel Andrés Breakdown of academic impact, for papers by Chizuko Kanbayashi Breakdown of academic impact, for papers by Gian Paolo Spinelli Breakdown of academic impact, for papers by I Zbieranowski Breakdown of academic impact, for papers by Su-Mi Chung
Rankless by CCL
2026